Research programme: complement membrane attack complex inhibitors - Regenesance
Alternative Names: MAC-iLatest Information Update: 16 Jul 2016
At a glance
- Originator Regenesance
- Class
- Mechanism of Action Complement membrane attack complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peripheral nervous system diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in Netherlands
- 30 Nov 2009 Preclinical trials in Peripheral nerve disorders in Netherlands (unspecified route)